Vanguard Global Advisers
ESPR

Vanguard Global Advisers’s Esperion Therapeutics ESPR Stock Holding History

Vanguard Global Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Sell
94,911
-53,879
-36% -$151K ﹤0.01% 2334
2026
Q1 		$408K Buy
+148,790
New +$471K ﹤0.01% 2133

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Vanguard Global Advisers's ESPR Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Esperion Therapeutics (ESPR) stake by 36% in Q2 2026, selling an estimated $151K and leaving 94,911 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

Vanguard Global Advisers first reported a position in ESPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $408K in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Vanguard Global Advisers held 94,911 shares of Esperion Therapeutics worth $300K as of Q2 2026.
  • Vanguard Global Advisers sold 53,879 Esperion Therapeutics shares in Q2 2026, an estimated $151K.
  • Esperion Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2334 holding.
  • Vanguard Global Advisers first reported a position in Esperion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Esperion Therapeutics position peaked at $408K in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.